dehaze, a Munich-based healthtech AI company, has
raised €3.2 million in a seed funding round led by YZR Capital and DN Capital,
with participation from Angel Invest, Zoho, and Better Ventures. The funding
will support the company’s efforts to develop a foundational AI model for
chronic disease detection.
dehaze’s platform uses causal AI to analyse large
volumes of patient data, enabling healthcare payers to identify individuals at
risk of chronic conditions earlier, improve intervention outcomes, and reduce
costs.
Chronic diseases remain the largest cost driver in
global healthcare systems, accounting for around 70 per cent of deaths and more
than $8 trillion in annual spending, according to the World Health
Organization. Despite the abundance of available health data, clinicians
typically review only a small fraction before making decisions, contributing to
a significant share of conditions going undetected at earlier, more treatable
stages.
dehaze aims to address this gap through a purpose-built
model designed specifically for healthcare data. Its system processes
heterogeneous datasets at scale and provides causal insights that support
decision-making for both clinicians and insurers. The company says its approach
can help reduce medical loss ratios while enabling earlier and more effective
treatment.
Marius Klages, co-founder and CEO of dehaze, said the
company was built in Munich from the ground up as a foundational AI model for
chronic disease detection, rather than as a chatbot or dashboard-style
solution:
Our customers are global from day one, because the
problem is global from day one. The speed at which payers are signing with us
confirms what we believed when we started: this is a category that will be
defined over the next few years, and dehaze is going to define it.
The new funding will be used to expand both the
technical and commercial teams and to further develop platform capabilities,
including features for recommending next-best actions and improving
traceability.